<code id='BA0ED71E15'></code><style id='BA0ED71E15'></style>
    • <acronym id='BA0ED71E15'></acronym>
      <center id='BA0ED71E15'><center id='BA0ED71E15'><tfoot id='BA0ED71E15'></tfoot></center><abbr id='BA0ED71E15'><dir id='BA0ED71E15'><tfoot id='BA0ED71E15'></tfoot><noframes id='BA0ED71E15'>

    • <optgroup id='BA0ED71E15'><strike id='BA0ED71E15'><sup id='BA0ED71E15'></sup></strike><code id='BA0ED71E15'></code></optgroup>
        1. <b id='BA0ED71E15'><label id='BA0ED71E15'><select id='BA0ED71E15'><dt id='BA0ED71E15'><span id='BA0ED71E15'></span></dt></select></label></b><u id='BA0ED71E15'></u>
          <i id='BA0ED71E15'><strike id='BA0ED71E15'><tt id='BA0ED71E15'><pre id='BA0ED71E15'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:Wikipedia    Page View:86646
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In